SCHEMBL5334461

SCHEMBL5334461

CCc1cc(NC(=O)Oc2ccccc2)n(CC)n1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.47
ALDH1A1 P00352 6/20 0.43
MAPT P10636 4/20 0.43
MEN1 O00255 4/20 0.43
KMT2A Q03164 4/20 0.43
GAA P10253 2/20 0.43
NPC1 O15118 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
PKM P14618 1/20 0.43
POLB P06746 1/20 0.43
MIF P14174 1/20 0.43
FAAH O00519 6/20 0.41
THRB P10828 2/20 0.41
HPGD P15428 1/20 0.41
KDM4E B2RXH2 1/20 0.41
GFER P55789 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5224672 0.88 RAB9A (0.48) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL1012925 0.86 MAPK14 (0.48) RAB9AGAAHPGD
SCHEMBL1015652 0.85 ALDH1A1 (0.54) RAB9AALDH1A1KMT2AGAALMNA
SCHEMBL5335193 0.84 ALDH1A1 (0.46) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL5334061 0.84 PKM (0.46) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL896549 0.78 RAB9A (0.46) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL4465670 0.77 MAPK14 (0.49) RAB9AHPGD
SCHEMBL29253954 0.75 RAB9A (0.51) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL25439464 0.75 FAAH (0.46) RAB9AALDH1A1MAPTMEN1KMT2A
SCHEMBL20064244 0.75 RAB9A (0.58) RAB9AALDH1A1MAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7288537-B2 Azetidine derivatives as CCR-3 receptor antagonists NOVARTIS AG (CH) 2007-10-30 US disclosed
US-20050222118-A1 Azetidine derivatives as ccr-3 receptor antagonists NOVARTIS AG (CH) 2005-10-06 US disclosed
EP-1487435-A1 AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS Novartis AG (CH) 2004-12-22 EP disclosed
WO-2003077907-A1 AZETIDINE DERIVATIVES AS CCR-3 RECEPTOR ANTAGONISTS NOVARTIS AG (CH) 2003-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222118-A1 Azetidine derivatives as ccr-3 receptor antagonists CCR3, CCR1, CCR9 RAB9A 608/4885ALDH1A1 2840/4885MAPT 4292/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.